Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: Connection refused in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa (inotuzumab ozogamicin)

besponsa (inotuzumab ozogamicin)

Перейти к контенту

Главное меню:

Разное
besponsa (inotuzumab ozogamicin)
inotuzumab ozogamicin (Besponsa) - scottishmedicines.org.uk, Inotuzumab ozogamicin - Wikipedia, About BESPONSA® | BESPONSA®, Besponsa | European Medicines Agency, Besponsa (Inotuzumab Ozogamicin) | Lymphoma News Today, Besponsa (inotuzumab ozogamicin) | TheSocialMedwork, BESPONSA™ (inotuzumab ozogamicin) | R/R B-Cell ALL , FDA Approves Besponsa (Inotuzumab Ozogamicin) for Acute , Inotuzumab Ozogamicin - National Cancer Institute.
BESPONSA is associated with a risk of liver problems and increased risk of death after stem cell transplant. BESPONSA can cause liver problems that can be severe, life-threatening, or fatal, including a condition called veno-occlusive disease (VOD). This condition can occur during treatment with BESPONSA or following subsequent treatment with a stem cell transplant. This condition was more common in patients who had elevated liver tests or who received dual alkylating agents in preparation for their stem cell transplant. Patients may be at a higher risk of VOD if they:. inotuzumab ozogamicin (BESPONSA®) is accepted for restricted use within NHSScotland. Indication under review: as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL).. History. In 2017 inotuzumab ozogamicin was approved by the European Commission and the FDA for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in 2017 under the trade name Besponsa (Pfizer/Wyeth)..
BESPONSA ® (inotuzumab ozogamicin) is a prescription medicine used to treat adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). It is not known if BESPONSA is safe and effective in children under 18 years of age.. The active substance in Besponsa, inotuzumab ozogamicin, is a monoclonal antibody (a type of protein) that has been linked to a small molecule, N-acetyl-gamma-calicheamicin dimethylhydrazide.. Besponsa (inotuzumab ozogamicin, previously CMC-544) is an approved therapy developed by Pfizer to treat adults with B-cell precursor acute lymphoblastic leukemia (ALL) whose disease has relapsed or who did not respond to standard therapy.. Besponsa (inotuzumab ozogamicin) is is a medication used for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). How to buy Besponsa (inotuzumab ozogamicin): You can order Besponsa from TheSocialMedwork if the drug has not been approved or is not available in your country.. BESPONSA ® (inotuzumab ozogamicin) is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).. The US Food and Drug Administration has approved the targeted therapy drug Besponsa (inotuzumab ozogamicin) for adults with B-cell precursor acute lymphoblastic leukemia (ALL) that is not getting better with treatment, or came back after treatment. B-cell precursor ALL is a type of cancer in which.
 
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню